(Q42656384)

4 November 2017

title

Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinum (English)

1 reference

4 November 2017

1 reference

1 reference

du Bois A

1

1 reference

4 November 2017

Lück HJ

2

1 reference

4 November 2017

Buser K

3

1 reference

4 November 2017

Meerpohl HG

4

1 reference

4 November 2017

Sessa C

5

1 reference

4 November 2017

Klaassen U

6

1 reference

4 November 2017

Meden H

7

1 reference

4 November 2017

Bochtler H

8

1 reference

4 November 2017

Diergarten K

9

1 reference

4 November 2017

publication date

1 March 1997

1 reference

4 November 2017

number of pages

6

1 reference

European Journal of Cancer

inferred from page(s)

published in

1 reference

4 November 2017

volume

33

1 reference

4 November 2017

issue

3

1 reference

4 November 2017

page(s)

379-384

1 reference

Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989009-0

7 January 2021

Salvage chemotherapy for epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989009-0

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989009-0

7 January 2021

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989009-0

7 January 2021

Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989009-0

7 January 2021

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989009-0

7 January 2021

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989009-0

7 January 2021

Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989009-0

7 January 2021

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989009-0

7 January 2021

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989009-0

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989009-0

7 January 2021

Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989009-0

7 January 2021

10.1016/S0959-8049(97)89009-0

Identifiers

DOI

1 reference

4 November 2017

1 reference